Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Representatives Worried OTC Plan B May Increase Adolescent STD Risk

This article was originally published in The Tan Sheet

Executive Summary

Political pressure could affect the pending FDA decision on Barr Labs' application for over-the-counter status for emergency contraceptive Plan B (levonorgestrel)
Advertisement

Related Content

Plan B May Prevent Vote On Crawford FDA Commissioner Confirmation
Plan B May Prevent Vote On Crawford FDA Commissioner Confirmation
Plan B May Prevent Vote On Crawford FDA Commissioner Confirmation
OTC Plan B Age Limits Would Reflect Political Taint In FDA Review – Wood
OTC Plan B Age Limits Would Reflect Political Taint In FDA Review – Wood
Barr Adds Preven To OTC Contraceptive Pipeline
Battle Over Plan B In Virginia Focusing On Minors, Colleges
Plan B Switch Decision Deadline Postponed To May
Plan B Behind-The-Counter Status Discouraged By Panel Members
Plan B Behind-The-Counter Status Discouraged By Panel Members

Topics

Advertisement
UsernamePublicRestriction

Register

PS096399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel